WHO pandemic treaty
EDITORIAL: The recent landmark agreement reached by member states of the World Health Organisation (WHO) represents a critical juncture in the global management of future pandemics.
After more than three years of complex and sometimes contentious negotiations, the WHO countries have successfully struck a deal to establish a comprehensive pandemic treaty aimed at addressing the severe inadequacies exposed during the Covid-19 crisis.
This agreement must be welcomed, as it lays a necessary foundation for greater global cooperation, preparedness, and equitable access to healthcare resources in future global health emergencies.
Central to the treaty is the introduction of the Pathogen Access and Benefit-Sharing System (PABS). This innovative mechanism is designed to streamline the rapid sharing of pathogen-related data with pharmaceutical firms, expediting the development and distribution of vaccines, diagnostics, and therapeutics.
By committing to this level of transparency and cooperation, the treaty directly addresses one of the greatest failures of the global response to Covid-19—the slow and uneven distribution of crucial medical resources. Ensuring that medical breakthroughs swiftly translate into universally accessible healthcare solutions is undoubtedly one of the treaty's most commendable components.
Another notable achievement of the agreement is its nuanced approach towards technology transfers. Technology transfer, particularly concerning pharmaceutical products developed during pandemics, has historically been a sticking point, with powerful pharmaceutical interests often prioritising intellectual property rights above public health needs.
The finalised text of the treaty states that such transfers must be 'mutually agreed,' thereby finding a pragmatic balance between protecting intellectual property and facilitating widespread access to essential health technologies. While this compromise may not satisfy all stakeholders fully, it is a significant step forward, showing that member states recognise the imperative of balancing commercial interests with public health necessities.
Additionally, the treaty contains a pivotal commitment by pharmaceutical manufacturers to allocate 20 percent of their real-time pandemic-related production to WHO-coordinated efforts. This clause directly addresses the stark inequities witnessed during the Covid-19 vaccine rollout, where wealthy nations secured large portions of early vaccine supplies, leaving many developing countries dangerously exposed.
This structured allocation will play a vital role in ensuring equitable access, offering a degree of protection against vaccine nationalism and commercial exploitation in future crises.
Despite its evident strengths, though, the treaty is not without challenges. Most notably, the absence of the United States, following its announced departure from the WHO, significantly undermines the treaty's global reach and effectiveness.
American participation and leadership have historically played key roles in international health responses. Without US involvement, there remains a potential gap in implementation and financing, as well as uncertainty regarding global leadership in health crises.
The true test of this agreement, however, will come in its practical implementation. Member states must not only ratify, but actively enforce and operationalise its provisions. Adequate funding, political commitment, and sustained global solidarity are crucial if the treaty is to transcend symbolic significance and achieve practical effectiveness. It will require governments to look beyond immediate national interests and embrace a genuinely cooperative stance on global health.
In welcoming this treaty, it is vital to recognise that pandemics are not isolated health events; they are global phenomena requiring robust, collective responses. This landmark agreement signifies a strong international consensus on the necessity of preparedness, equity, and transparency in managing future pandemics.
However, the real work begins now. The international community must remain vigilant and committed to ensuring that these ambitious aspirations translate into concrete actions, safeguarding humanity's collective health and well-being in the years to come.
Copyright Business Recorder, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
3 days ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Business Recorder
5 days ago
- Business Recorder
US expected to block Gaza ceasefire vote at Security Council
UNITED NATIONS: The UN Security Council will vote Wednesday on a resolution calling for a ceasefire and unrestricted humanitarian access in Gaza, a measure expected to fail due to a US veto. It is the 15-member body's first vote on the subject since November, when the United States – a key Israeli ally – also blocked a text calling for an end to fighting. The new resolution, seen by AFP, 'demands an immediate, unconditional and permanent ceasefire in Gaza respected by all parties.' It also calls for the 'immediate, dignified and unconditional release of all hostages held by Hamas and other groups.' Underlining a 'catastrophic humanitarian situation' in the Palestinian territory, the resolution additionally demands the lifting of all restrictions on the entry of humanitarian aid into Gaza. US-backed Gaza aid group to halt distribution on Wednesday, UN to vote on ceasefire demand It will be put to vote at 4:00 pm Wednesday (2000 GMT), but several diplomats indicated to AFP that they expected the United States to wield its veto power. They added that the representatives from the 10 elected members of the Council, who will introduce the text, tried in vain to negotiate with the American side. The veto, if applied, would be the first by Washington since US President Donald Trump took office in January. That scrutiny has increased over flailing aid distribution in Gaza, which Israel blocked for more than two months before allowing a small number of UN vehicles to enter in mid-May. The United Nations said that was not enough to meet the humanitarian needs. A US-backed relief effort called the Gaza Humanitarian Fund (GHF) has also come under criticism for going against long-standing aid principles by coordinating relief efforts with a military belligerent. Israeli bombardment on Wednesday killed at least 16 people in the Gaza Strip, including 12 in a single strike on a tent housing displaced people, the Palestinian territory's civil defense agency told AFP. On Tuesday, 27 people were killed in southern Gaza when Israeli troops opened fire near a GHF aid site, with the military saying the incident was under investigation. Riyad Mansour, the Palestinian ambassador to the UN, on Tuesday urged the Council to act. 'All of us will be judged by history as to how much have we done in order to stop this crime against the Palestinian people,' he said. Israel's ambassador to the UN Danny Danon lambasted the draft text. 'This resolution doesn't advance humanitarian relief. It undermines it. It ignores a working system in favor of political agendas,' he was to tell the council, according to remarks released by his office. 'It ignores the one party still endangering civilians in Gaza: Hamas.'
Express Tribune
5 days ago
- Express Tribune
US CDC COVID vaccine advisor Dr. Lakshmi Panagiotakopoulos resigns: Reuters
Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021. Photo:REUTER Listen to article Pediatric infectious disease expert Dr Lakshmi Panagiotakopoulos of the US CDC resigned on Tuesday as co-leader of a working group that advises outside experts on COVID-19 vaccines and is leaving the agency, said two sources familiar with the move. Panagiotakopoulos said in an email to work group colleagues that her decision to step down was based on the belief she is "no longer able to help the most vulnerable members" of the US population. In her role at the Centers for Disease Control and Prevention's working group of the Advisory Committee on Immunization Practices, she co-led the gathering of information on topics for presentation. Her resignation comes one week after Health Secretary Robert F Kennedy Jr, a long-time vaccine skeptic who oversees the CDC, the Food and Drug Administration and the National Institutes of Health, said the COVID vaccine for healthy children and healthy pregnant women had been removed from the CDC's recommended immunization schedule. The move was a departure from the process in which ACIP experts meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the agency's director made a final call. The committee had not voted on the changes announced by Kennedy and the CDC does not yet have a permanent director. Two days after Kennedy's announcement, the CDC published a vaccine schedule online saying that COVID-19 vaccines remain an option for healthy children aged 6 months to 17 years when parents and doctors agree that it is needed. It had previously recommended updated COVID vaccines for everyone aged six months and older, following the guidance of the panel of outside experts. Two sources said Panagiotakopoulos did not include a specific reason for her departure. Panagiotakopoulos did not return requests for comment. "Unfortunately for me, this is a personal decision," Panagiotakopoulos wrote in an email to members of the working group that was read to Reuters by a source who received it. "My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role." The committee is scheduled to meet on June 25-27 and is expected to deliberate and vote on recommendations for use of COVID-19 vaccines, according to one of the sources who was not authorized to speak publicly.
